Delving into the Latest Updates on OT-202 with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

OT 202, OT-202

Target

Syk

Mechanism

Syk inhibitors(Spleen tyrosine kinase inhibitors)

Therapeutic Areas

Eye Diseases

Active Indication

Xerophthalmia

Inactive Indication-

Originator Organization

Ocumension Therapeutics

Active Organization

Ocumension Therapeutics

Zhuhai Essex Bio-Pharmaceutical Co., Ltd.

Inactive Organization-

Drug Highest PhasePhase 2

First Approval Date-

Regulation-

To explore the optimal therapeutic dose of OT202 eye drops for the treatment of moderate to severe dry eyes, and to evaluate the safety and efficacy of OT202 eye drops for the treatment of moderate to severe dry eyes, so as to provide a basis for the design and dosage selection of the next clinical trial research.

Start Date27 Mar 2023

Sponsor / Collaborator

Ocumension Therapeutics

[+1]

CTR20213138 / CompletedPhase 1

OT202滴眼液单次/多次给药在中国健康受试者中的随机、双盲、安慰剂对照的安全性、耐受性及药代动力学特性的I期临床研究

[Translation] A randomized, double-blind, placebo-controlled phase I clinical study on the safety, tolerability and pharmacokinetic properties of single/multiple administration of OT202 eye drops in healthy Chinese subjects

主要目的评价OT202滴眼液单次剂量递增和多次给药在健康受试者中的安全性和耐受性。次要目的评价OT202滴眼液单次剂量递增和多次给药在健康受试者中的药代动力学特征。

[Translation]

Primary objective To evaluate the safety and tolerability of single-dose ascending and multiple-dose administration of OT202 eye drops in healthy subjects. Secondary objective To evaluate the pharmacokinetic characteristics of single-dose ascending and multiple-dose administration of OT202 eye drops in healthy subjects.

Start Date30 Dec 2021

Sponsor / Collaborator

Ocumension Therapeutics

[+1]

100 Clinical Results associated with OT-202

Login to view more data

100 Translational Medicine associated with OT-202

Login to view more data

100 Patents (Medical) associated with OT-202

Login to view more data

100 Deals associated with OT-202

Login to view more data

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Xerophthalmia	Phase 2	CN	Zhuhai Essex Bio-Pharmaceutical Co., Ltd.	27 Mar 2023
Xerophthalmia	Phase 2	CN	Ocumension Therapeutics	27 Mar 2023

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


CTR20223244 (Corporate Publications) Manual	Phase 2	Xerophthalmia	213	OT-202	qxuwvhxdkx(tamioogxtl) = OT-202达到预设的主要终点指标 rrnwrtmqtl (iybelamhfg ) Met	Positive	14 Mar 2024
				安慰剂